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Background: Organic anion-transporting polypeptides (OATPs) are influx transporters that 
mediate intracellular uptake of selective endogenous and xenobiotic compounds. Identification 
of new molecular targets and discovery of novel targeted therapies is top priority for pancreatic 
cancer, which lacks any effective therapy.
Materials and methods: We studied expression of OATP 1A2, 1B1, and 1B3 in pancreatic 
cancer tissue and in cell lines. Formalin-fixed paraffin-embedded biopsy material of 12 human 
pancreatic cancers was immunohistochemically assessed for protein expression of the three 
studied influx transporters. Immunohistochemistry was evaluated by experienced pathologists 
and quantified by use of an automated image analysis system. BxPC-3 and MIA PaCa-2 
pancreatic cancer cell lines were used to quantify transcripts of OATP 1B1 and 1B3.
Results: OATP 1A2, 1B1, and 1B3 proteins were found ubiquitously expressed in all studied 
cases. Quantification performed by HistoQuest system revealed that mean intensity was 53 for 
1A2, 45 for 1B1, and 167 for OATP 1B1/1B3 on a range scale 0–250 units. At mRNA level, 
1B1 and 1B3 were overexpressed in both studied cancer cell lines but not in normal pancreatic 
tissue.
Conclusion: OATPs 1A2, 1B1, and 1B3 are highly expressed in pancreatic adenocarcinoma. 
We suggest that expression of these transporters in pancreatic cancer justify research efforts 
towards discovery of novel therapeutics targeting OATPs.
Keywords: organic anion-transporting polypeptides, targeted therapy, transporter
Introduction
Pancreatic carcinoma is the most deadly among cancers, ranked fourth as a cause of 
cancer-related deaths in the economically developed world.1,2 Characteristically, in 
Europe, new diagnoses of pancreatic cancer almost equaled the deaths caused by this 
disease in 2008.3
Surgery remains the gold standard for the treatment of pancreatic cancer, if 
diagnosed early. However, even in cases of surgically resected tumors, the outcome 
remains poor, and adjuvant therapy can offer marginal benefits.2,4 In advanced pancreatic 
cancer, the outlook is even worse. Extensive research has failed to produce any therapy 
efficient enough to substantially extend the median survival of treated patients beyond 
6 months. Currently available therapies remain palliative on their intent.5–7 Therefore, 
identification of new molecular targets and discovery of novel targeted therapies is 
top priority for pancreatic cancer research.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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The organic anion transporting polypeptides (OATPs) 
superfamily comprises 11 polypeptide molecules that share 
a largely common structure with 12 putative transmembrane 
regions and a large extracellular loop between the 9th and 
10th transmembrane domains8 (Figure 1). They operate as 
influx transporters that mediate the transmembrane uptake 
of various endogenous and xenobiotic anion compounds. 
Besides their characteristic expression in normal tissues, 
OATPs have been found overexpressed in several cancers, and 
it was such data that prompted us to undertake investigation of 
these transporters as potential therapeutic targets.9 Regarding 
pancreatic cancer, Abe et al, showed expression of OATP 
1B3 in human pancreatic cancer on mRNA and protein level 
in a single case.10 To our knowledge, this is the first study that 
systemically assessed the expression profile of three OATPs 
(1A2, 1B1, and 1B3) in pancreatic cancer.
Materials and methods
Tissue samples and anti-OATP antibodies
Formalin-fixed paraffin-embedded tissue samples of human 
pancreatic cancer were retrieved from the archives of the 
Department of Pathology, Chatzikosta General Hospital, 
Ioannina, Greece. The patients were diagnosed in the 
period 2000–2008. Their median age was 69 years; six were 
female and six male. Histologically, eight cases were diag-
nosed as poorly differentiated pancreas adenocarcinomas, 
and four cases had intermediate differentiation.
The samples were assessed for expression of OATP 1B1 
and 1B1/1B3 by using the mESL and mMDQ antibodies 
respectively (PROGEN Biotechnik, Heidelberg, Germany). 
Expression of OATP 1A2 was evaluated in 11 samples by 
polyclonal anti-OATP 1A2 antibody (Atlas Antibodies AB, 
Stockholm, Sweden). A polyclonal anti-OATP 1B3 antibody 
(Atlas Antibodies AB, Stockholm, Sweden) was also used 
that recognizes C-terminal region of OATP 1B3, on the aim 
to monitor the expression of the 1B3 transporter as a single 
entity. All antibodies were diluted with Dako REAL™ 
Antibody Diluent (DAKO, Code S2022) to the final working 
concentration (Table 1). The DAKO Autostainer/PT link 
system was used for the immunostaining process.
cell lines
Two pancreatic cancer cell lines, BxPC-3 (CRL-1687TM) 
and MIA PaCa-2 (CRL-1420TM), were obtained from the 
American Tissue Culture Collection (ATCC, Manassas, 
VA) to be used in this study. MIA PaCa-2 originated from 
a male14 and BxPC-3 from a female donor.15 Cells were 
routinely cultured in RPMI-1640 medium (PAN Biotech, 
Aidenbach, Germany) supplemented with 10% fetal calf 
serum (Invitrogen Life Technologies, Paisley, Scotland) 
and 1% penicillin/streptomycin (Invitrogen) under standard 
culture conditions.
immunohistochemistry
Tissue sections of 3–4 µm width were cut using a microtome 
and applied on microscope slides. Slides were incubated 
overnight at 65°C to enable optimal tissue–glass adhesion. 
Next, slides were immersed in DAKO’s PT-Link containing 
preheated (65°C) target retrieval solution, at pH 9 (DAKO 
Code S2375), treated at 93°C for 20 minutes in order to 
achieve deparaffinization, rehydration, and heat-induced 
epitope-retrieval (HIER). After cooling back to 65°C, slides 
were inserted in DAKO Autostainer system for the rest 
of the immunohistochemistry procedure. The mESL and 
mMDQ antibodies were applied on slides for 70 minutes, 
while for the polyclonal anti-OATP1A2 and anti-OATP1B3 
antibodies incubation time was set to 60 minutes. The 
endogenous peroxidase was blocked using Daco REAL 
peroxidase blocking solution (Code S2023) for 10 minutes. 
DAKO’s special engineered Dextran backbone enriched with 
peroxidase molecules and goat secondary antibody molecules 
Figure  1  ribbon  representation  of  the  three-dimensional  model  of  organic 
anion-transporting  polypeptide  1B3. TM  domains,  a  probable  substrate  binding 
site and the conserved amino acid side chains. The model was built by Modeller 
program (san Francisco, cA, UsA) by using the structure template of the Escherichia 
coli glycerol-3-phosphate transporter (PDB 1pw4).24,25 in blue color the potential 
location of the substrate binding site (the putative translocation pathway) according 
to former mutagenesis studies is indicated.26 conserved amino acid side-chains can 
also be seen on this figure.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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against rabbit and mouse immunoglobulins (Dako REAL™ 
EnVision™/HRP, Rabbit/Mouse ENV , Code Code K5007) 
was applied on slides for 20 minutes followed by a 5 minute 
Dako REAL™ DAB+ Chromogen (DAKO, Code K5007) 
detection system and a 2 minute hematoxylene (QS H-3404 
Vector Laboratories) treatment. Finally, sections were 
dehydrated with alcohol/xylene baths and stabilized with 
mounting medium.
immunohistochemistry evaluation
Immunostaining intensity was assessed by two experienced 
pathologists, who graded it, using endothelial cells and tissue 
macrophages as internal controls (Table 2). Quantitation was 
done by HistoQUEST (TissueGnostics, Vienna, Austria) 
system in values of gray from 0 to 25011,12 (Figures 2 and 3).
sLcO1A2, sLcO1B1, and sLcO1B3  
mRNA expression quantification
Total RNA was isolated from both cell lines grown to 
subconfluency using the Trizol reagent (Invitrogen). We also 
used human liver RNA (purchased from Stratagene La Jolla, 
USA) and human pancreas RNA (purchased from Clontech, 
Saint-Germain-en-Laye, France) for control purposes.
The concentration, purity, and integrity of RNA samples 
were determined on a Nanodrop ND-1000 (Kisker-Biotech, 
Steinfurt, Germany) and by agarose gel electrophoresis.
Reverse transcription of total RNA to cDNA (2 µg) was 
done by using the high capacity cDNA reverse transcription 
kit (Applied Biosystems, Foster City, USA) as recommended 
by the manufacturer. The quantification of SLCO/OATP 
mRNA transcripts was done by using TaqMan® real-time 
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Table 2 immunohistochemical expression of OATPs. score scale 
(0, 1+, 2+, 3+) reflecting antibody product expression intensity
Patient  
number
Sex Age Differentiation p1A2 mESL mMDQ
1 F 71 intermediate + + +++
2 F 67 Poor ++ + +++
3 F 74 Poor +++ + ++
4 M 56 Poor +++ + ++
5 M 80 intermediate ++ + ++
6 F 55 Poor ++ + ++
7 F 78 Poor +++ + ++
8 F 70 Poor +++ + +++
9 M 72 intermediate +++ + ++
10 M 67 Poor ++ + ++
11 M 65 Poor ++ + ++
12 M 70 intermediate nA  + ++
Abbreviations:  F,  female;  M,  male;  nA,  not  applicable;  OATP,  organic  anion-
transporting polypeptide.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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PCR method (Applied Biosystems). The following TaqMan 
assays were used: hs00272374_m1 for OATP 1A2 and 
hs00251986_m1 for OATP 1B3. For accurate normalization 
of real time RT-PCR data we included four reference genes 
in the analysis, namely 18S rRNA (PN 4310893E; Applied 
Biosystems), ACTB (PN 4326315E; Applied Biosystems), 
CYC1 (PrimerDesign Ltd, Southampton, UK), and UBC 
(PrimerDesign Ltd). The target gene amplification mixture 
contained 5 µL 2× TaqMan® Gene Expression PCR Master 
Mix (Applied Biosystems), 0.5 µL of the appropriate Gene 
Expression Assay, 10 ng template cDNA diluted in 2.5 µL 
nuclease free water, and 2 µL nuclease free water. 5´–3' 
exonuclease activity of the DNA polymerase was measured 
with the ABI 7900HT Fast real time PCR system was 
equipped with SDS 2.3 software (Applied Biosystems). 
All samples were amplified in duplicates. Results were 
imported into Prsim GraphPad for further analysis. Specimens 
exhibiting cycle threshold (Ct) values higher than 38 were 
considered to be negative, and comparable cDNA amounts 
in the experimental samples were calculated according to 
Hellemans et al.13 Values are expressed as n-fold difference 
according to a calibrator set to value 1. As a calibrator, RNA 
pooled from a panel of human tissue samples and cell lines 
analyzed was taken, and expression values in the calibrator 
were set to 1.
Results
immunohistochemistry
The three studied polypeptides were found ubiquitously 
expressed in all studied biopsy cases. Both methods used 
confirmed extensive immunostaining of the entire cancer cell 
tissue with the antibodies used (Table 2; Figures 2 and 4).
Specifically, OATP 1A2 expression signal was weak 
in one sample and moderate to strong in all others. The 
HistoQUEST quantification analysis returned a mean intensity 
of 53.88 units with a standard error (SE) of 7.19. OATP 1B1 
A B
C D
Figure  4  immunohistochemical  staining  of  pancreatic  adenocarcinoma  tissue 
sample  from  a  77-year-old  female  patient  diagnosed  with  poorly  differentiated 
adenocarcinoma of the head of the pancreas. A) p1A2 antibody (×40), B) mesL 
antibody (×100), C) mMDQ antibody (×200), D) p1B3 antibody (×40).
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Figure  2  OATP  immunohistochemical  expression  intensity  as  was  assessed  by 
histoQUesT  (Tissuegnostics)  automated  immunohistochemistry  analysis  system. 
The Y-axis represents mean intensity measured in values of grey scale from 0 to 250. 
Abbreviation: OATP, organic anion-transporting polypeptide.
A
C
EF
D
B
Figure 3 histoQUesT (Tissuegnostics) expression analysis. Pictures A, C, and E 
represent the identification and segmentation of cells and nuclei. Pictures B, D, and F 
demonstrate the diaminobenzidine signal intensity for each cell in the studied area.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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was found to be weakly expressed in all 12 cases with mean 
intensity 45.10 units (SE 3.15). Immunostaining for mMDQ 
(OATP 1B1/1B3) was proved the most intense. Nine cases 
demonstrated moderate expression, three cases stained strong, 
and HistoQUEST assessment showed a mean intensity of 
167.90 units (SE 8.27). Interestingly, the anti-OATP 1B3 p1B3 
antibody failed to detect expression of its nominal target in 
the same cancer tissue material (Figure 4), although it stained 
normal human liver tissue, which was used in this case as a 
positive control for p1B3 antibody (Figure 5).
cell lines
OATP 1B1 and 1B3 mRNA expression in the two cell lines 
was comparable to that in normal liver, which was taken as 
a control, because both these transporters are considered 
“liver-specific”. Their mRNA expression, however, in normal 
pancreas was either undetectable (OATP 1B1) or 30–60 times 
lower than in normal liver (OATP 1B3) (Figure 6).
Discussion
The need for discovery of new molecular targets and 
the development of innovative targeted therapeutics in 
pancreatic cancer is indisputably illustrated by the fact that 
of the 36 orphan-designated products for pancreatic cancer 
by the United States Food and Drug Administration, none 
received marketing approval on this indication during the 
last 25 years.16 We considered that expression of organic 
anion-transporting polypeptides in a wide range of cancers 
along with their unique capacity for energy-independent 
intracellular transport of xenobiotics makes them reasonable 
targets for potential development of novel cancer therapeutics 
against hard-to-treat cancers.17–20
We opted to investigate the expression of OATP 1A2, 
1B1, and 1B3 in pancreatic cancer, because of their 
common and distinctive ability to facilitate intracellular 
uptake of microcystin cyclopeptides, which are natural 
toxins produced from cyanobacteria.21 Microcystins exert 
cytotoxic effects through depletion of glutathione, generation 
of reactive oxygen species, and strong inhibition of protein 
phosphatases 1 and 2A.22 We surmise that these natural 
toxins are of potential pharmacological interest because they 
offer opportunities to engineer analogs optimized to induce 
selective cancer toxicity in OATP expressing tumors.9
The OATPs investigated in this study were all found 
to be ubiquitously expressed in pancreatic cancer: OATP 
1A2, 1B1, and 1B3 protein expression was documented in 
biopsy samples and OATP 1B1 and 1B3 mRNA in cell lines. 
Quantification analysis showed an increased expression of 
1B1/1B3 compared with 1A2 and 1B1, which indicates 
enhanced expression potential for OATP 1B3 in these tumors. 
It should be noted that the inability to detect OATP 1B3 
C-terminal region with p1B3 antibody opposes the strong 
positive mMDQ signal in the same samples, which confirmed 
the presence of the 24 amino acid N-terminal epitope of  OATP 
1B3. Interestingly, we obtained similar results in a colon 
cancer study in which we identified an abundant presence of 
1B3 protein when studied with mMDQ monoclonal antibody 
but not with the p1B3 antibody.23 We speculate that these 
findings might possibly be related to unknown mutation near 
the C-terminal end of 1B3 polypeptide in cancers. This is 
currently under investigation in our laboratory.
Finally, we consider that demonstration of OATP 1B3 and 
1B1 mRNA expression in BxPC-3 and MIA PaCa-2 human 
pancreatic cell lines flags them as appropriate candidates for 
in-vitro studying of OATP targeted anticancer compounds.
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